Chronic Obstructive Pulmonary Disease (COPD) Biologics Market to Reach US$ 1.67 Billion by 2033 at 12.1% CAGR as Dupilumab and Mepolizumab Lead Precision Therapy Revolution

AUSTIN, Texas and TOKYO -- According to DataM Intelligence, The Chronic Obstructive Pulmonary Disease (COPD) Biologics Market Size reached US$ 604.70 million in 2024 and is projected to reach US$ 1,678.90 million by 2033, expanding at a CAGR of 12.1% during the forecast period 2025-2033. The COPD Biologics Market is transforming respiratory care by introducing monoclonal antibodies that target type 2 inflammation pathways, reducing exacerbations and hospitalizations in eosinophilic COPD.

The shift from symptomatic management to biologic add-on therapies reflects a broader transformation toward precision medicine, exacerbation prevention, improved quality of life, and personalized treatment for eosinophilic phenotypes. Unlike conventional inhalers, biologics like dupilumab (Dupixent, Sanofi/Regeneron) and mepolizumab (Nucala, GSK) block IL-4/IL-13 or IL-5 signaling, delivering significant reductions in moderate-to-severe exacerbations (30-34% for dupilumab, 15-25% for mepolizumab in pivotal trials). This innovation is not just additive; it is a paradigm shift in severe COPD management, regulatory milestones, and eosinophil-guided therapy.

Download Exclusive Sample Report: https://www.datamintelligence.com/download-sample/chronic-obstructive-pulmonary-disease-copd-biologics-market?jd

Browse in-depth TOC on "Chronic Obstructive Pulmonary Disease (COPD) Biologics Market"
45 - Tables
46 - Figures
180 - Pages

Industry Trends & 2025 Developments

-Dupilumab Momentum: In 2025, Dupixent (dupilumab) saw rapid uptake post-2024 approvals, with post-hoc analyses from BOREAS/NOTUS trials confirming consistent benefits regardless of emphysema and significant FEV1/quality-of-life gains.
-Mepolizumab Approval & Expansion: GSK's Nucala (mepolizumab) gained FDA approval in May 2025 for eosinophilic COPD, with MATINEE trial data showing 15-25% exacerbation reduction; China filings advanced in 2025.
-Head-to-Head Insights: Indirect comparisons in 2025 highlighted dupilumab's numerical advantages in exacerbations, lung function (FEV1 ~83 mL greater), and symptom improvement over mepolizumab.
-Pipeline & Real-World Growth: Increased eosinophil testing and biologic adoption in G7 countries drove market acceleration in 2025.

Market Segmentation - Growth Anchors

By Drug Class
In 2024, Dupilumab dominated with 54.1% revenue share, driven by its first-in-class approvals (EMA July 2024, FDA September 2024, Japan March 2025) and strong efficacy in reducing exacerbations and improving FEV1 in eosinophilic COPD. Mepolizumab follows closely, boosted by FDA approval in May 2025 as add-on for inadequately controlled eosinophilic COPD.

By Route of Administration
Subcutaneous injection is the sole and dominant mode, offering convenient at-home or clinic administration every 2-4 weeks.
By Distribution Channel
Hospital Pharmacies and Specialty Pharmacies lead due to specialist prescribing, reimbursement requirements, and patient monitoring for biologics.

Regional Insights: North America & Asia Pacific

North America
North America dominates with 43.5% revenue share in 2024, led by:
-High COPD burden, advanced diagnostics, and rapid adoption of new biologics.
-Strong payer coverage and specialist access in the U.S.
-Key players Sanofi/Regeneron (Dupixent) and GlaxoSmithKline (Nucala) driving launches and real-world evidence in 2025.

Asia Pacific
Asia Pacific is the fastest-growing region, expected to expand at a CAGR of 8.1% over the forecast period, supported by:
-Rising COPD prevalence from urbanization/smoking in China, India, and Southeast Asia.
-Improving access to biologics and regulatory progress (e.g., filings/approvals).
-Growing healthcare investments and eosinophilic phenotype awareness.

Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/chronic-obstructive-pulmonary-disease-copd-biologics-market?jd

Competitive Landscape: Leaders Driving the Future

Sanofi / Regeneron Pharmaceuticals Inc.
Sanofi and Regeneron Pharmaceuticals Inc. dominate the COPD biologics landscape with Dupixent (dupilumab), a groundbreaking IL-4/IL-13 inhibitor that became the first biologic approved for COPD in 2024, showcasing up to 34% reduction in exacerbations and rapid global adoption by 2025. Their focus on type 2 inflammation has positioned them as leaders, with ongoing real-world studies reinforcing its efficacy in eosinophilic phenotypes.

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK) advances the market through Nucala (mepolizumab), an IL-5 antagonist that secured FDA approval in May 2025 as an add-on therapy for eosinophilic COPD, drawing on its established success in asthma management. This biologic offers 15-25% exacerbation reductions, bolstering GSK's portfolio and driving growth in severe COPD segments.

Other Key Players
Emerging competitors in the COPD biologics space, such as those in late-stage trials, contribute through innovative IL-5 or IL-4 targeted therapies, focusing on regional expansions in Asia-Pacific and Europe. Pipeline players are enhancing the market with novel mechanisms, aiming for broader indications and improved patient outcomes by 2025 and beyond.

Buy This Exclusive Report at Just USD 4350 Only: https://www.datamintelligence.com/buy-now-page?report=chronic-obstructive-pulmonary-disease-copd-biologics-market

Strategic Outlook

-Biologic Approvals & Adoption - Dupilumab and mepolizumab milestones will expand the eosinophilic COPD segment.
-Precision Phenotyping - Eosinophil-guided therapy will drive targeted prescribing.
-Exacerbation Reduction Focus - Superior outcomes in severe cases will boost value-based reimbursement.
-Regional Expansion - North America's leadership combined with Asia-Pacific's fastest growth will accelerate global access.

Conclusion

The Chronic Obstructive Pulmonary Disease (COPD) Biologics Market, projected to rise from US$ 604.70 million in 2024 to US$ 1,678.90 million by 2033, is central to precision respiratory care, exacerbation prevention, and improved outcomes for eosinophilic COPD. With North America holding 43.5% share and Asia-Pacific setting the fastest CAGR of 8.1%, the sector offers compelling opportunities for pulmonologists, biotech firms, payers, and investors focused on targeted inflammation therapies.

Contact Us:
DataM Intelligence 4market Research LLP
USA: +1 877-441-4866
Email: Sai.k@datamintelligence.com
Visit Our Website: https://www.datamintelligence.com/

About DataM Intelligence
DataM Intelligence is a renowned provider of market research, delivering deep insights through pricing analysis, market share breakdowns, and competitive intelligence. The company specializes in strategic reports that guide businesses in high-growth sectors such as nutraceuticals and AI-driven health innovations.

This release was published on openPR.